文献速递妇科生殖医学

宫颈癌保留生育功能手术与生育力保存:生育意愿及生殖产科结局

Fertility-sparing surgery and fertility preservation in cervical cancer: The desire for parenthood, reproductive and obstetric outcomes.
PubMed 文献 · Gynecol Oncol · 2021-09-25

荷兰单中心回顾性研究纳入2009至2020年75例接受保留生育功能治疗的宫颈癌患者,其中34例接受阴道根治性宫颈切除术,9例根治性子宫切除,32例放化疗;26例启动生育力保存,23例(88.5%)成功保存。中位随访49个月,5例复发死亡;VRT后尝试妊娠者妊娠率61.9%,活产率75.0%;RH或放化疗后3例代孕妊娠(21.4%)。

要点

  • 早期宫颈癌VRT可获良好生殖结局且不损害肿瘤安全。
  • 根治性子宫切除或放化疗者生育力保存联合代孕是可行选择。
  • 多数宫颈癌幸存者治疗后仍保持生育意愿。

核心结论

  • 许多宫颈癌幸存者最终仍希望成为父母;早期疾病中VRT显示良好生殖结局且不损害肿瘤安全;需性腺毒性治疗者生育力保存和代孕为获得生物学后代提供有前景的替代方案。

研究设计与样本

  • 荷兰三级转诊中心2009年1月至2020年1月纳入所有<45岁接受保留生育功能治疗的浸润性宫颈癌女性,共75例;34例接受VRT,9例RH,32例接受(化疗)放疗;26例启动生育力保存;通过病历和问卷获取生殖意愿与结局数据。

主要发现

  • 26例启动生育力保存者中23例(88.5%)通过胚胎、卵母细胞和卵巢组织冷冻成功保存生育力。
  • 中位随访49个月,5例患者出现复发并死亡。
  • 58例患者获取生殖结局,89.6%在癌症治疗后保持生育意愿。
  • VRT后尝试妊娠者(n=24)妊娠率61.9%;15例患者怀21次妊娠,活产15次,活产率75.0%。
  • RH或(化疗)放疗后,使用冻融材料建立3例代孕妊娠(21.4%),新生儿结局良好。

关键数值与推荐

  • VRT后尝试妊娠者妊娠率61.9%(n=24)。
  • VRT后活产率75.0%(15次活产/21次妊娠)。
  • RH或(化疗)放疗后代孕妊娠率21.4%(3例)。
  • 生育力保存成功率88.5%(23/26)。
  • 89.6%患者治疗后保持生育意愿。

临床怎么用

  • 对早期宫颈癌有生育意愿者,VRT可作为保留生育功能的选择,需告知其妊娠率与活产率数据及肿瘤安全性。
  • 对需根治性子宫切除或放化疗者,应讨论生育力保存(胚胎、卵母细胞、卵巢组织冷冻)及代孕作为未来生育的可行途径。
  • 治疗后应关注患者生育意愿变化并提供生殖咨询与辅助生殖支持。

局限性

  • 回顾性单中心研究,样本量有限。
  • 生殖结局仅58例可获取,存在缺失数据。
  • 代孕妊娠例数少(3例),结果需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the desire for parenthood and reproductive outcomes of young cervical cancer survivors who underwent fertility-sparing surgery or fertility preservation procedures for invasive cervical cancer. METHODS: All women <45 years who underwent fertility-sparing treatment for invasive cervical cancer in a tertiary referral center in the Netherlands between January 2009 and January 2020 were identified. Fertility-sparing treatment options included Vaginal Radical Trachelectomy (VRT) for patients with early-stage disease and fertility preservation techniques (FP) when requiring Radical Hysterectomy (RH) or chemoradiotherapy. Data on reproductive intentions - and outcomes were retrieved from medical files and questionnaires. RESULTS: 75 patients were identified of whom 34 underwent VRT, 9 RH and 32 had (chemo)radiotherapy. 26 patients started FP of whom 23 (88.5%) successfully preserved fertility through cryopreservation of embryos, oocytes and ovarian tissue. After a median follow-up of 49 months, 5 patients developed recurrent disease and died. Reproductive outcomes were retrieved in 58 patients. 89.6% maintained their desire for parenthood after cancer treatment. Following VRT, we report a pregnancy rate of 61.9% among the patients attempting conception (n = 24). 15 patients conceived 21 pregnancies which resulted in 15 live-births, yielding a live-birth rate of 75.0%. Following RH or (chemo)radiotherapy, 3 surrogate pregnancies were established (21.4%) using frozen-thawed material with good neonatal outcomes. CONCLUSION: Many cervical cancer survivors maintain the desire to become parents eventually. In early-stage disease, VRT shows good reproductive outcomes without compromising oncological safety. For those requiring gonadotoxic treatment fertility preservation and gestational surrogacy provides a promising alternative for achieving a biological offspring.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. van der Plas RCJ, Bos AME, Jürgenliemk-Schulz IM, et al. Fertility-sparing surgery and fertility preservation in cervical cancer: The desire for parenthood, reproductive and obstetric outcomes. Gynecol Oncol. 2021. PMID: 34583837. doi:10.1016/j.ygyno.2021.09.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。